Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SciSparc Ltd
< Previous
1
2
Next >
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
August 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
SPRC
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
July 22, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 17, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
July 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
SPRC
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
July 08, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
TSX-V:MIZA-P.V
SciSparc Secures Strategic Advantage with Grant of European Patent
May 31, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc to Acquire AutoMax
April 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
March 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
March 21, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
March 18, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
March 14, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
March 12, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
March 08, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
March 07, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
March 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
February 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
January 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
January 24, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
January 19, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
January 04, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
December 13, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
December 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Adopts Limited Duration Shareholder Rights Plan
November 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
November 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
November 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
November 24, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit